Camp4 Therapeutics has a total of 39 patents globally, out of which 2 have been granted. Of these 39 patents, more than 51% patents are active. United States of America is where Camp4 Therapeutics has filed the maximum number of patents, followed by Europe and Hong Kong (S.A.R.). Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Camp4 Therapeutics.
Camp4 Therapeutics was founded in the year 2016. The Company operates as a bio-technology company. The Company develops therapies for the treatment of various deceases.
Do read about some of the most popular patents of Camp4 Therapeutics which have been covered by us in this article and also you can find Camp4 Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Camp4 Therapeutics patent portfolio.
How many patents does the founder and the CEO of Camp4 Therapeutics have?
The founders Leonard Zon has 0 patent and Richard Young has 0 patent and CEO Josh Mandel-Brehm has 0 patent.
How many patents does Camp4 Therapeutics have?
Camp4 Therapeutics has a total of 39 patents globally. These patents belong to 11 unique patent families. Out of 39 patents, 20 patents are active.
How Many Patents did Camp4 Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
Year of Patents Filing or Grant | Camp4 Therapeutics Applications Filed | Camp4 Therapeutics Patents Granted |
2023 | 1 | 1 |
2022 | 4 | 1 |
2021 | 1 | – |
2020 | 6 | – |
2019 | 14 | – |
2018 | 13 | – |
How many Camp4 Therapeutics patents are Alive/Dead?
How Many Patents did Camp4 Therapeutics File in Different Countries?
Countries in which Camp4 Therapeutics Filed Patents
Country | Patents |
United States Of America | 11 |
Europe | 5 |
Hong Kong (S.A.R.) | 4 |
Canada | 4 |
China | 3 |
Where are Research Centres of Camp4 Therapeutics Patents Located?
The Research Centre for all the Camp4 Therapeutics patents is the United States of America.
10 Best Camp4 Therapeutics Patents
US20210254056A1 is the most popular patent in the Camp4 Therapeutics portfolio. It has received 47 citations so far from companies like Mary Kay Inc., Listen Technologies Corporation and Abbvie Inc.
Below is the list of 10 most cited patents of Camp4 Therapeutics:
Publication Number | Citation Count |
US20210254056A1 | 47 |
WO2019036430A1 | 9 |
WO2020037069A1 | 5 |
WO2020081329A1 | 4 |
US20200208128A1 | 3 |
WO2019195854A1 | 3 |
US20210118524A1 | 2 |
CN111094581A | 2 |
WO2019195855A1 | 2 |
WO2019195789A1 | 2 |
What Percentage of Camp4 Therapeutics US Patent Applications were Granted?
Camp4 Therapeutics (Excluding its subsidiaries) has filed 9 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 2 have been granted leading to a grant rate of 50.0%.
Below are the key stats of Camp4 Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Camp4 Therapeutics?
Law Firm | Total Applications | Success Rate |
Goodwin Procter Llp | 9 | 50.00% |
List of Camp4 Therapeutics Patents
Camp4 Therapeutics Patents | Title |
US11542290B2 | Phenothiazine Derivatives And Uses Thereof |
US11266655B2 | Methods And Compositions For Treating Urea Cycle Disorders |
US20230282314A1 | Characterizing Functional Regulatory Elements Using Machine Learning |
US20230257410A1 | Phenothiazine Derivatives And Uses Thereof |
US20220168316A1 | Methods And Compositions For Treating Urea Cycle Disorders |
US20220107328A1 | Methods Of Treating Liver Diseases |
US20210118524A1 | Identifying Therapeutic Targets By Discovering Interactions Between Non-Coding Variants And Candidate Genes |
US20200208128A1 | Methods Of Treating Liver Diseases |
EP3773597A4 | Phenothiazine Derivatives And Uses Thereof |
EP3668993A4 | Methods Of Treating Liver Diseases |
CN111447934A | Methods And Compositions For Treating Urea Cycle Disorders, In Particular Otc Deficiency |
CN111094581A | Methods Of Treating Liver Diseases |
WO2023034983A3 | Modulation Of Gene Transcription Using Antisense Oligonucleotides Targeting Regulatory Rnas |
WO2023122762A1 | Modulation Of Gene Transcription Using Antisense Oligonucleotides Targeting Regulatory Rnas |
CA3094481A1 | Phenothiazine Derivatives And Uses Thereof |
CA3072346A1 | Methods Of Treating Liver Diseases |
HK40046680A | Phenothiazine Derivatives And Uses Thereof |
HK40032170A | Methods And Compositions For Treating Urea Cycle Disorders, In Particular Otc Deficiency |
HK40030309A | Methods Of Treating Liver Diseases |
HK40029501A | Methods Of Treating Liver Diseases |
US20210254056A1 | Identification And Targeted Modulation Of Gene Signaling Networks |
US20210161997A1 | Treating Diseases Via Targeted Modulation Of Gene Signaling Networks |
US20200316038A1 | Methods And Compositions For Treating Urea Cycle Disorders, In Particular Otc Deficiency |
EP3836929A1 | Methods Of Treating Liver Diseases |
EP3773618A1 | Treating Diseases Via Targeted Modulation Of Gene Signaling Networks |
EP3691656A1 | Methods And Compositions For Treating Urea Cycle Disorders, In Particular Otc Deficiency |
CN111971063A | Treating Diseases Via Targeted Modulation Of Gene Signaling Networks |
WO2020210642A1 | Methods And Compositions For Treating Urea Cycle Disorders |
WO2020081329A1 | Methods And Compositions For Modulating Pcsk9 And Angptl3 Expression |
WO2020037069A1 | Methods Of Treating Liver Diseases |
WO2019195854A1 | Compositions And Methods For Treating Phenylketonuria |
WO2019195855A1 | Treating Diseases Via Targeted Modulation Of Gene Signaling Networks |
WO2019195789A1 | Phenothiazine Derivatives And Uses Thereof |
WO2019071276A1 | Methods And Compositions For Treating Urea Cycle Disorders, In Particular Otc Deficiency |
WO2019036430A1 | Methods Of Treating Liver Diseases |
WO2018204764A1 | Identification And Targeted Modulation Of Gene Signaling Networks |
WO2018204762A1 | Methods And Compositions Of Modeling Diseases With Hematopoietic Cell Systems |
CA3095040A1 | Treating Diseases Via Targeted Modulation Of Gene Signaling Networks |
CA3078247A1 | Methods And Compositions For Treating Urea Cycle Disorders, In Particular Otc Deficiency |
What are Camp4 Therapeutics key innovation segments?
What Technologies are Covered by Camp4 Therapeutics?
The chart below distributes patents filed by Camp4 Therapeutics